Nov 09, 2020 6:30am EST ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease
Oct 30, 2020 6:30am EDT ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium
Oct 23, 2020 6:30am EDT ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants
Oct 21, 2020 6:30am EDT ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab
Oct 13, 2020 6:30am EDT ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference
Sep 10, 2020 6:30am EDT ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference